CERo Therapeutics (CERO) details February 2026 poster presentation in 8-K filing

Rhea-AI Filing Summary

CERo Therapeutics Holdings, Inc. filed a current report to note that it has prepared a poster presentation for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster is included as Exhibit 99.1 and is described as summary information meant to be read alongside the company’s other SEC filings and public announcements.

The company states that the poster presentation speaks only as of its date and that it expressly disclaims any obligation to update it, even if circumstances change. The filing is administrative in nature and does not include financial results or major corporate transactions.

false 0001870404 0001870404 2026-02-04 2026-02-04 0001870404 CERO:CommonStockParValue0.0001PerShareMember 2026-02-04 2026-02-04 0001870404 CERO:WarrantsEachWarrantExercisableForOneTwothousandthsOfShareOfCommonStockMember 2026-02-04 2026-02-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 4, 2026

CERO THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40877		81-4182129
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

201 Haskins Way, Suite 230, South San Francisco, CA		94080
(Address of principal executive offices)		(Zip Code)

(650) 407-2376

Registrant’s telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CERO		None
Warrants, each warrant exercisable for one two-thousandths of a share of Common Stock		CEROW		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Information.

CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), has prepared a poster presentation that will be presented at the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in the poster presentation is summary information that should be considered within the context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The poster presentation speaks as of the date of this Current Report on Form 8-K. While the Company may elect to update the poster presentation in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Poster Presentation (February 2026)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 4, 2026	CERO THERAPEUTICS HOLDINGS, INC.
	By:	/s/ Chris Ehrlich
	Name:	Chris Ehrlich
	Title:	Chief Executive Officer

2

FAQ

What did CERo Therapeutics (CERO) disclose in this 8-K filing?

CERo Therapeutics disclosed that it prepared a poster presentation for the Transplantation and Cellular Therapy Meetings starting February 4, 2026. The poster is filed as Exhibit 99.1 and is characterized as summary information that should be read with the company’s other SEC filings and announcements.

What is Exhibit 99.1 in CERo Therapeutics’ (CERO) 8-K?

Exhibit 99.1 is a poster presentation dated February 2026 prepared for the Transplantation and Cellular Therapy Meetings. The company describes it as summary information and emphasizes it should be considered within the broader context of its existing SEC filings and public communications.

Does CERo Therapeutics (CERO) commit to updating the poster presentation?

CERo Therapeutics explicitly states that the poster presentation speaks only as of its date. While the company may choose to update it in the future, it specifically disclaims any obligation to revise the poster to reflect subsequent events or circumstances.

What event is associated with CERo Therapeutics’ (CERO) poster presentation?

The poster presentation is associated with the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. CERo Therapeutics prepared the poster for this conference and filed it as Exhibit 99.1 to provide investors access to the same summary information shared at the meeting.

Does this CERo Therapeutics (CERO) 8-K include financial results?

This 8-K does not present financial results. It focuses on the company’s preparation of a poster presentation for the February 2026 Transplantation and Cellular Therapy Meetings and the inclusion of that poster as Exhibit 99.1, along with standard exhibit and signature information.

Who signed CERo Therapeutics’ (CERO) 8-K related to the poster presentation?

The 8-K was signed on behalf of CERo Therapeutics Holdings, Inc. by Chris Ehrlich, the company’s Chief Executive Officer. His electronic signature appears on the filing dated February 4, 2026, fulfilling the requirement that a duly authorized officer execute the report.